We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

273 hedge funds and large institutions have $6.45B invested in Amicus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 88 increasing their positions, 100 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 28

64% more capital invested

Capital invested by funds: $3.93B → $6.45B (+$2.52B)

9% more funds holding

Funds holding: 251273 (+22)

7% more call options, than puts

Call options by funds: $85.2M | Put options by funds: $79.6M

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0.33% less ownership

Funds ownership: 107.52%107.19% (-0.33%)

12% less repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 100

Holders
273
Holders Change
+22
Holders Change %
+8.76%
% of All Funds
4.81%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
50
Increased
88
Reduced
100
Closed
28
Calls
$85.2M
Puts
$79.6M
Net Calls
+$5.69M
Net Calls Change
-$18M

FOLD Hedge Fund Activity: Q4 2020 in Review

273 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2020, worth a combined $6.45B — up 64% from $3.93B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new FOLD positions and 28 closed out — a net gain of 22 holders — while 88 added to existing stakes and 100 trimmed.

The largest buyer was Lone Pine Capital, opening a new position worth an estimated $137M. The largest seller was Janus Henderson Group, cutting an estimated $58.5M.

  • 273 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2020, up from 251 in Q3 2020.
  • Funds reported $6.45B of Amicus Therapeutics stock for Q4 2020, up 64% quarter-over-quarter.
  • 50 funds opened new Amicus Therapeutics positions in Q4 2020 and 28 closed out, a net change of +22 holders.
  • The largest Amicus Therapeutics buyer in Q4 2020 was Lone Pine Capital, an estimated $137M added.
  • The largest Amicus Therapeutics seller in Q4 2020 was Janus Henderson Group, an estimated $58.5M sold.

Based on aggregated 13F filings for Q4 2020.